Historique
Article de Périodique
Use of buprenorphine in pregnancy: patient management and effects on the neonate (2003)
(Buprénorphine pendant la grossesse : prise en charge du patient et effets chez le nouveau-né)
Auteur(s) :
JOHNSON, R. E. ;
JONES, H. E. ;
FISCHER, G.
Année
2003
Page(s) :
S87-S101
Sous-type de document :
Revue de la littérature / Literature review
Langue(s) :
Anglais
Refs biblio. :
95
Domaine :
Drogues illicites / Illicit drugs
Thésaurus mots-clés
BUPRENORPHINE
;
OPIACES
;
DEPENDANCE
;
GROSSESSE
;
NOUVEAU-NE
;
SYNDROME DE SEVRAGE
;
MERE
;
PRISE EN CHARGE
Note générale :
Drug and Alcohol Dependence, 2003, 70, (2, Suppl. 1), S87-S101
Note de contenu :
tabl.
Résumé :
ENGLISH :
It is estimated that 55-94% of infants born to opioid-dependent mothers in US will show signs of opioid withdrawal. Buprenorphine has been reported to produce little or no autonomic signs or symptoms of opioid withdrawal following abrupt termination in adults. To date, there have been 21 published reports representing approximately 15 evaluable cohorts of infants exposed to buprenorphine in utero. Of approximately 309 infants exposed, a neonatal abstinence syndrome (NAS) has been reported in 62% infants with 48% requiring treatment; apparently greater than 40% of these cases are confounded by illicit drug use. The NAS associated with buprenorphine generally appears within 12-48 h, peaks at approximately 72-96 h, and lasts for 120-168 h. These results appear similar to or less than that observed following in utero exposure to methadone. From a review of the literature, buprenorphine appears to be safe and effective in both mother and infant with an NAS that may differ from methadone both qualitatively and quantitatively. (Review's abstract.)
Affiliation :
Clinc., Sci. Regul. Aff., Reckitt Benckiser Pharmaceutic.
Etats-Unis. United States.
Etats-Unis. United States.